Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: 1. Aged≥18 years old and ≤70 years old when signing the informed consent; regardless of gender; 2. Body weight\>40kg; 3. Histopathology or cytology confirmed as advanced NSCLC which is not suitable for radical surgical resection; 4. At least one measurable lesion according to the RECIST 1.1 criteria; according to the CT or MRI cross-sectional imaging, the diameter of a single lesion ≤8 cm, or the maximum diameter of a single lesion ≤5 cm and the number of lesions ≤5 (including metastatic lesions). 5. Imaging examination showed no tumor thrombus in the portal vein/inferior vena cava; 6. Acceptable hemopoietic ability: hemoglobin (HGB) \>90g/L (no blood transfusion within two weeks), absolute neutrophil count (ANC) \>1.5×10\^9/L, platelet count \>1.0×10\^11/L, absolute lymphocyte count (ALC)\>500×10\^9/L; 7. Prothrombin time (PT)/international normalized ratio (INR) \<1.5 ULN and partial thromboplastin time (PTT)/activated partial thromboplastin time (APTT) \<1.5 ULN; 8. Acceptable liver and kidney functions: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN in subjects without liver metastases and ≤3.5 upper limit of normal (ULN) in those with liver metastases; bilirubin≤1.5 ULN (excluding hyperbilirubinemia or non-liver-derived hyperbilirubinemia); creatinine ≤1.5 ULN and creatinine clearance rate≥40 mL/min; 9. Women of child-bearing age must be negative for pregnancy test at 7 days before initiation of the treatment. 10. Eastern Cooperative Oncology Group (ECOG) scores≤1. 11. Expected survival no less than 6 months. Exclusion Criteria: 1. History of any chemotherapy within 2 weeks before a single blood collection; 2. Participating in other clinical trials in the past 30 days; 3. Current on systemic steroid or steroid inhalers; 4. Active brain metastasis or spinal cord compression 5. Uncontrollable pleural and peritoneal effusion requiring clinical treatment or intervention; 6. Active bleeding, and thrombotic diseases requiring treatment; 7. Uncontrolled infectious diseases, such as baseline hepatitis B virus (HBV) DNA≥2000 IU/mL, positive for anti-human immunodeficiency virus （HIV） antibody and hepatitis C virus (HCV)-RNA; Other active infection with clinical significance; 8. Organ failure; Heart: Grade III and IV ; or with hypertension uncontrolled by the standard treatment, history of myocarditis or myocardial infarction within 1 year; Liver: Class C according to the Child-Turcottei-Pugh System (CTP); Kidneys: Kidney failure and uremic syndrome; Lungs: Serious symptoms of respiratory failure; Brain: Disturbance of consciousness; 9. Allergic diathesis and allergic to immunotherapy or relevant drugs; 10. Pregnancy or lactation; 11. History of other active malignancies in the past 5 years, excluding basal or squamous skin carcinoma, superficial bladder cancer, and breast cancer in situ which have completely healed and require no follow-up treatment; 12. Serious autoimmune diseases or immunodeficiency disease, including those with confirmed severe autoimmune diseases and requiring long-term use (over 2 months) of systemic immunosuppressants (steroids) or having immune-mediated symptomatic diseases, such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (eg., Wegener's granulomatosis); 13. Any mental diseases, including dementia and changes in mental status that may influence the understanding about the informed consent and questionnaire; 14. Judged as serious uncontrollable diseases by the researchers, or other conditions that may interfere with the treatment and therefore being ineligible.